Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 77,800 shares, a drop of 47.0% from the September 15th total of 146,700 shares. Approximately 1.2% of the company’s shares are short sold. Based on an average trading volume of 2,690,000 shares, the short-interest ratio is presently 0.0 days.
Institutional Investors Weigh In On Adial Pharmaceuticals
An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 0.48% of Adial Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 16.41% of the stock is owned by hedge funds and other institutional investors.
Adial Pharmaceuticals Stock Performance
Shares of NASDAQ:ADIL opened at $0.95 on Friday. Adial Pharmaceuticals has a 52 week low of $0.77 and a 52 week high of $4.17. The firm has a 50 day simple moving average of $1.00 and a 200 day simple moving average of $1.26.
About Adial Pharmaceuticals
Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.
Read More
- Five stocks we like better than Adial Pharmaceuticals
- What is the S&P/TSX Index?
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.